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Abstract
Background: The FinnishIPF registry is a prospective, longitudinal national registry study on the epidemiology of
idiopathic pulmonary fibrosis (IPF). It was designed to describe the characteristics, management and prognosis of
prevalent and incident IPF patients. The study was initiated in 2012.
Methods: We present here results limited to five university hospitals. Patients with IPF were screened from hospital
registries using ICD-10 diagnosis codes J84.1 and J84.9. All patients who gave informed consent were included and
evaluated using novel diagnostic criteria. Point prevalence on the 31st of December in 2012 was calculated using
the reported population in each university hospital city as the denominator.
Results: Patients with ICD-10 codes J84.1 and J84.9 yielded a heterogeneous group – on the basis of patient
records assessed by pulmonologists only 20–30 % of the cases were IPF. After clinical, radiological and histological
re-evaluation 111 of 123 (90 %) of patients fulfilled the clinical criteria of IPF. The estimated prevalence of IPF was
8.6 cases/100 000. 60.4 % were men. Forty four percent of the patients were never-smokers. At diagnosis, the
patients’ mean age was 73.5 years and mean FVC was 80.4 % and DLCO 57.3 % of predicted.
Conclusions: Our results suggest that hospital registries are inaccurate for epidemiological studies unless patients
are carefully re-evaluated. IPF is diagnosed in Finland at a stage when lung function is still quite well preserved.
Smoking in patients with IPF was less common than in previous reports.
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Background
According to previous epidemiological studies, the preva-
lence of idiopathic pulmonary fibrosis (IPF) varies greatly
depending on the methods and diagnostic criteria used [1].
As novel treatment options for IPF are emerging [2, 3],
accurate epidemiological data on IPF is needed. There are
several ongoing national and international projects that aim
to determine the epidemiology of IPF [4–7].
The updated ATS/ERS/JRS/ALAT recommendations on
the diagnosis and management of IPF [8] emphasize the
role of high-resolution computed tomography (HRCT). So
far, very few epidemiological studies exist where patients
have been re-evaluated based on the novel guidelines, and
the ones that do exist, are not geographically extensive [9].
Our study was designed to obtain accurate data on the
epidemiology and demographics of carefully re-evaluated
IPF patients from five university cities in Finland.
Mortality in IPF is high, but recent studies suggest, that
the severity of disease at diagnosis has an effect on mortal-
ity – all-cause mortality is relatively low in patients with
mild to moderate lung impairment [10, 11]. Delayed access
to tertiary care defined as the time from the onset of the
dyspnea to the date of the initial evaluation at a tertiary care
center is associated with a higher mortality rate in IPF,
independent of disease severity [12]. Although these results
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are not surprising, they accentuate the importance of early
diagnosis in IPF.
Cigarette smoking is identified as a risk factor for IPF
[13]. In a recent report of a Danish cohort 81 % of IPF
patients were current or ex- smokers [14]. It has been
previously postulated, that smoking would present a
survival benefit in IPF patients [15], but this result has
not been confirmed in later studies.
The FinnishIPF study was initiated to assess the
characteristics, diagnostic accuracy, treatment, exacer-
bations and survival of patients with IPF. Enrolling
patients and collecting follow-up data are on continu-
ing basis. In this report, we present epidemiological
results on systematically collected, re-evaluated IPF
patients. Re-evaluation was performed by a multi-
disciplinary team of pulmonary physicians, radiologists
and pathologists in all of the five university hospitals
in Finland.
Methods
Patient recruitment and data collection
In order to evaluate systematically the nationwide preva-
lence of IPF in different geographical areas, we narrowed
the study population to five university hospital cities and
their populations at the end of the year 2012. The
university hospitals represent tertiary hospitals, the most
specialized level of public health care. All IPF patients
who gave informed consent and lived during 2012 in the
university hospital cities Helsinki, Turku, Tampere,
Kuopio, or Oulu (see Fig. 1 for geographical location)
were included. In Finland, patients are referred to
specialist centers according to their living address and
practically all IPF patients are initially evaluated at the
public health care system.
The patient registries of five university hospitals were
screened for the ICD-10 diagnosis code J84.1 (other
interstitial pulmonary diseases with fibrosis) and J84.9
(interstitial pulmonary disease). The diagnostic criteria
of the ATS/ERS statement 2011 [8] were used. An
experienced pulmonary physician re-evaluated the pa-
tients’ data by reading through the patient charts.
70–80 % of patients’ diagnoses did not meet the clinical
criteria of idiopathic pulmonary fibrosis. The disquali-
fied cases were other idiopathic interstitial pneumonias
(IIP), most commonly NSIPs (non-specific interstitial
pneumonia), fibrotic conditions linked to connective
tissue diseases or other types of pulmonary fibrosis with
known etiology (e.g. asbestosis). Only patients with con-
firmed IPF diagnosis were asked to give informed
consent. 65–89 % (average 76 %) of the re-evaluated
IPF patients gave consent. The patient data was added
to a secure, electronic registry database. At baseline,
data on demographics, risk factors and comorbidities
were collected (Table 1). At follow-up visits lung
function parameters as well as events such as hospi-
talizations, disease exacerbations, changes in medica-
tion were recorded (Table 1). The lung function
values were evaluated using the Finnish reference
values [16]. The dates of death were confirmed from
an electronic population registry. The immediate and
underlying cause of death was collected from the death
certificates (an up-to-date registry kept by Statistics
Finland). Missing data was not computed as we had most
data on all patients available. Only 4 patients did not have
spirometry and only 2 patients did not have smoking
history data.
Re-evaluation of radiological findings
The baseline CT scans were centrally re-evaluated by
one experienced chest radiologist (over 20 years of
experience) and a radiology resident. Most of the scans
were carried out prior to 2010 with a time range from
2003 to 2012. HRCT scans were evaluated on all of the
123 patients with the exception of one patient, whose
evaluation was based on spiral CT. The quality of the
spiral CT was considered diagnostic and the patient
was therefore not excluded from the study. The
scanning protocols and used CT scanners in each
center varied. The obtained slice thickness was mainly
1–1.25 mm and the slices were captured in 10–40 mm
intervals, one volume HRCT was performed. In 21
patients, expiratory HRCT scans were available. In 13
patients, HRCT had been performed in both supine
and prone positions. Six patients had HRCT scan only
in the prone position, but they also had a supine helical
CT with i.v. contrast media. In two patients, a helical
scan with i.v. contrast media, from which HRCT recon-
structions were calculated, was available. Altogether 35
patients had a helical scan, 30 with and five without
i.v. contrast media. Of the 122 HRCT scans image
quality was satisfactory in 119 cases and poor in
three, mostly due to motion artifacts. Still, these three
HRCT scans with inferior image quality were consid-
ered diagnostic and the patients were not excluded
from the study. The scans were categorized into three
groups: 1) usual interstitial pneumonia (UIP) pattern,
2) possible UIP pattern, and 3) inconsistent with
UIP pattern [8]. The presence of a hiatal hernia was
assessed when suitable radiological data was available,
uncertain findings were not included. Honeycombing
as well as other HRCT features were evaluated accord-
ing to Fleischner Society’s glossary of terms for thoracic
imaging [17].
Re-evaluation of surgical lung biopsies
Surgical lung biopsy was performed in 27 (22 %) patients.
Three samples were not available for re-evaluation and in
each of these cases initial evaluation was considered to be
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Fig. 1 The geographical location and areas of the five university hospital cities in Finland where the cohort was collected and their population.
The number of people living in these cities was 1.29 million and it represented 24 % of the total population in Finland
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valid. The biopsies were re-evaluated according to the
most recent ATS/ERS guidelines by two experienced
pathologists (RK, EL-B) of whom RK is additionally a
pulmonologist. The samples were categorized into four
groups 1) UIP, 2) probable UIP, 3) possible UIP or 4)
not UIP.
Ethical considerations
Approval from the Helsinki University Hospital ethical
committee was obtained, and this approval was accepted
by ethical committees of the remaining four university
hospitals. The National Institute of Health and Welfare
gave authorization to screen patients from all Finnish
hospitals which have a unit of respiratory medicine with
the consent of the physician in charge. Patients who
gave their informed consent were included. Patients who
had died during the year 2012 before giving consent
were not included.
Statistical methods
The statistical analysis was carried out by experienced
researcher (MK) using SPSS 20.0 for Windows (SPSS™
Illinois, Chicago©). Percentages and mean values
(95 % CI) were used to describe the data. Kruskall-
Wallis test and X2 test (p < 0.05) were used to com-
pare the differences between the groups.
Results
Subject characteristics
Table 2 shows the characteristics of the IPF patients
who met the used IPF criteria. 60.4 % were men. The
mean age of patients at diagnosis was 73.5 years. Only
8.1 % of patients were current smokers. The most
common symptoms at the onset of the disease were dry
cough (48 of the 103 patients, 46.6 % who had symptom
data available) and dyspnea (46/103, 44.7 %). Eleven
patients (10.6 %) were asymptomatic at diagnosis. The
mean delay from the onset of symptoms to the date of
diagnosis was 1.9 years (range 0–16 years, SD 2.9). The
mean FVC at diagnosis was 80.4 % of predicted
(Table 2). The distribution of FVC and DLCO (%
predicted) of the IPF patients in five university hos-
pital cities did not differ from one another (one-way
ANOVA).
Radiological and histopathological re-evaluation
Table 3 shows the classification of patients according
to HRCT re-evaluation. Patients with a HRCT finding
inconsistent with UIP pattern whose diagnosis was not
confirmed by a surgical lung biopsy were dropped out
Table 2 Characteristics of the study population (N = 111) mean
(95 % CI) or %
Mean or % 95 % CI Number of observations
Age 73.5 71.8 – 75.2 111
Gender (%) 111
Men 60.4
Women 39.3
BMIa (kg/m2) 28.1 27.2 – 29.0 98
Smoking (%) 109
Never 44.1
Former 45.9
Current 8.1
FVCb % pred. 80.4 77.4 – 83.3 107
FVC (L) 2.9 2.7 – 3.1 107
DLCO/VAc % pred. 78.4 75.3 – 81.5 104
DLCO % pred. 57.3 54.4 – 60.2 104
Definitions of abbreviations: aBMI Body Mass Index; bFVC Forced Vital Capacity,
cDLCO(VA) Diffusing Capacity of Carbon Monoxide (divided by
Alveolar Volume)
Table 1 Parameters collected to the FinnishIPF registry
Basic information ID, gender, date of birth
Height, weight, body mass index
Smoking (pack years), occupation, exposures
Medical history, chronic illnesses
Medication
Diagnostic
information
Symptoms, date of onset
Date of diagnosis
FVC(L), FVC % of predicted, FEV1(L), FEV1 % of
predicted, DLCO/VA % of predicted and DLCO %
of predicted
Chest X-ray
High resolution computed tomography of the
lung (HRCT)
Biopsies, bronchoalveolar lavage samples, laboratory
findings
6-minute walk test (meters)
Familial or sporadic IPF
Follow-up
information
Changes in condition
FVC(L), FVC % of predicted, FEV1(L), FEV1 % of
predicted, DLCO % of predicted, DLCO/VA % of
predicted
Laboratory findings
High resolution computed tomography of the
lung (HRCT)
6-minute walk test (meters)
Changes in medication
Hospitalization
Date of lung transplantation
Date of death, cause of death
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of the final study population (N = 11). The patients
having a radiological possible UIP pattern who were
not biopsied (N = 10) were still included in the study,
as all patients were evaluated in a multidisciplinary
meeting to have IPF. From the 11 patients who were
excluded from the initial cohort due to radiological re-
evaluation, eight had a HRCT pattern more typical of
NSIP than UIP. One looked more like sarcoidosis and
one patient who had undergone irradiation due to
breast cancer was considered having radiation-induced
fibrosis. One patient had an undetermined interstitial
lung disease, possible exposures were looked for but
none were found in the registry data. Radiological
honeycombing was initially seen in 80 % of cases and
in the re-evaluation 76 % of cases. The presence or
absence of honeycombing was not mentioned in 11 %
of the initial readings despite most of these scans
were read as typical UIP. The initial readings
were mostly prior to the new ATS/ERS criteria,
which can explain why honeycombing was not always
mentioned.
A group of patients classified as having a radio-
logically typical UIP pattern (N = 87) had gone through
surgical lung biopsy (N = 12) of which 10 samples were
available for histopathological re-evaluation. One
patient with “not UIP pattern” in sparse lung biopsy
was, however, considered as IPF after multidisciplin-
ary evaluation and follow-up. Eighteen HRCT scans
were classified as “inconsistent with UIP”. In this
group seven lung biopsies were performed; histo-
pathological re-evaluation confirmed four UIP pat-
terns, one probable UIP pattern, one possible UIP
and one pattern with “not UIP” (Table 3). After a
final multidisciplinary evaluation only the one pa-
tient with “not UIP” pattern in surgical lung biopsy
was excluded from the cohort. Thus, the final study
population used for estimating disease prevalence
consisted of 111 confident IPF patients from the
university hospital cities (Fig. 1). The results of the
radiological and histological re-evaluation are sum-
marized in Table 3. A hiatal hernia was seen in 42.3 %
(47/111) of the patients.
Prevalence of registered IPF patients in Finland
The overall prevalence was 8.6 cases/100 000 (Table 4).
The number of patients in relation to the local popula-
tion as well as the participation rates was different
between the university hospital cities (p < 0.001, p =
0.0208, X2-test respectively). In 2012, 17 patients of
these 111 cases were newly diagnosed. Information on
familial or sporadic IPF was available in 92/111 pa-
tients. Patient reported history (two or more IPF cases
in the family) was used to identify familial form.
Altogether six patients (6.5 % of the valid) had familial
IPF.
Deaths during 2012
Of the 111 study participants 14 died before the end of
the year 2012. Of the 14 deceased patients 6 were women
and 8 men. The mean age at death was 75.5 years. At
diagnosis the mean FVC of predicted was 75.3 % and
mean DLCO/VA of predicted 75.3 %. The median survival
was 44.9 months after diagnosis. IPF was considered to be
the immediate cause of death in 7 (50 %) of the cases.
Pneumonia was the second most common immediate
cause affecting 5 patients (36 %). Other two non-IPF-
related immediate causes of death were intestinal
strangulation and rupture of abdominal aortic
aneurysm. IPF was considered to be underlying cause
of death in 12 cases. In the two cases described above,
Table 3 Results of the radiological and histopathological re-evaluation, showing the number of biopsy confirmed cases and number
of patients included in the study. There was no significant difference in the diagnostic accuracy between the five university hospitals.
After multidisciplinary evaluation altogether 111 patients were considered to have IPF
Histopathological finding
Radiological finding n (%) N:O of biopsies UIP Probable UIP Possible UIP Not UIP IPF in multidisciplinary evaluation (%)
UIP pattern 87 (70.7) 10 7 1 1 1 87
Possible UIP pattern 18 (14.6) 7 6 1 18
Inconsistent with UIP pattern 18 (14.6) 7 4 1 1 1 6
Total 123 24 17 3 2 2 111 (90.2)
Table 4 The population, number of patients included in the
study, deaths, and prevalence 31 th December 31, 2012 in
different regions
City Population IPF patients
n (%)
Number of deaths (%) Prevalence
Helsinki 603968 36 (32.4) 3/36 (8.3) 6.0
Turku 180225 17 (15.3) 2 /17(11.8) 9.4
Tampere 217421 21 (18.9) 1/21 (4.8) 9.7
Kuopio 105136 17 (15.3) 3/18 (16.7) 17.0
Oulu 190847 20 (18.0) 5/20 (25.0) 10.5
Total 1297597 111 (100) 14/111 (12.6) 8.6
# = Total population of the cities (Tilastokeskus, Statistic Finland 31 December
2012 [25]
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the underlying cause of death was intestinal strangula-
tion and aortic atherosclerosis.
Smoking
Data on smoking was available in 98.2 % (109/111) of
patients. Forty-four point one percent (44.1 %) were never-
smokers, 45.9 % ex - and 8.1 % current smokers. On
average, ex-smokers had an exposure of 27.3 (SD± 16.4)
pack-years and current smokers of 29 (SD± 14.7) pack-years.
Discussion
In this study we present baseline data of IPF patients in
Finland. Our results indicate, that careful multidisciplin-
ary evaluation of patients is necessary for obtaining ac-
curate data on IPF epidemiology. Our results also show,
that patients are diagnosed at a mild-moderate disease
stage in Finland (over 50 % of patients have FVC above
80 %), which should be taken into account when drug
reimbursement decisions are made in the future. Our
study confirms that ICD-10 does not provide sufficient
details for IPF diagnostics [18]. Other interstitial pul-
monary diseases with fibrosis (J84.1) includes over 200
disease entities, which can lead to misclassification and
overdiagnosis of patients if patients are not re-evaluated.
In our study, as many as 70–80 % of the ICD-10
screened cases proved not to be IPF after clinical re-
evaluation. As the awareness and classification of IIPs is
getting more precise, it is extremely important to de-
velop the diagnostic coding to meet the clinical needs.
Our results contradict another recent study on IPF epi-
demiology [19] where the diagnostic code of ICD-9 were
used as equivalent to IPF, and the results indicated a rising
prevalence of IPF. When compared to a previous study
from Finland [20], the prevalence seems in fact lower than
10 years before (16–18/100 000 [20] vs. 6.0–17.0/100 000).
The accuracy of the HRCT diagnosis in all the five
university hospitals was shown to be high. In the radio-
logical re-evaluation process, the presence of honey-
combing was considered as one of the hardest things to
define. Traction bronchiectasis and areas with combined
emphysema and fibrosis can often be misread as honey-
combing [21, 22], which may lead to overdiagnosis of
IPF. On the other hand, mild honeycombing can be
missed due to the conventional noncontiguous HRCT
technique. The wider use of volumetric HRCT will
probably ease the detection of honeycombing when mul-
tiplanar reconstructions from the thin slices will become
available. The number of lung biopsies was low in our
study 27/123 (22 %) possibly due to novel guidelines.
After re-evaluation of histopathology, only one patient
was excluded from our cohort suggesting that very few
patients nowadays get a histopathological diagnosis,
suggesting that the diagnostic accuracy of histopathology
in tertiary hospitals is high.
Geographical differences in IPF prevalence
In the UK, Navaratnam and colleagues have shown the
incidence of IPF to vary regionally; it was highest in North
West England [23]. Our results showed also regional
differences and the highest prevalence of IPF was found in
Eastern Finland, Kuopio. One explanation might be the
high participation rate in Kuopio, which did not, however,
account for the entire difference found. Smoking did not
explain the high prevalence in Kuopio either, as the lowest
numbers of smokers were found in Kuopio. In a previous
Finnish study on sporadic and familial pulmonary fibrosis
[20] it was suggested that familial IPF originated from
Eastern Finland, from a cluster of multiplex families.
Additionally, asbestos mining has taken place in the years
1904 – 1975 in a small town near Kuopio. The differences
in IPF prevalence numbers between the university cities
make the correct estimation of total number of patients
more difficult. An ongoing study extending to local
hospitals and the entire population will probably help in
determining, whether there is a true geographical variation
in the prevalence of IPF in Finland.
Severity of IPF at diagnosis
According to our results, most IPF patients were diag-
nosed at a mild/moderate stage of the disease measured
with lung function (FVC and DLCO at diagnosis). X-ray
and spirometry are widely available in the Finnish primary
health care centers, which could promote an earlier diag-
nosis. Nintedanib is not yet in use in Finland and pirfeni-
done treatment is reimbursed at the FVC range 50–80 %.
Thus, over 50 % of our patients had lung function over
the upper limit of this range. Our results warrant re-
evaluation of the indications for drug therapy, when at
best, the drug therapies only inhibit lung function decline.
Indeed, the U.S. FDA recently approved pirfenidone for
the treatment of idiopathic pulmonary fibrosis without
limits of the disease severity and perhaps the indication in
Europe will expand in the future. It is noteworthy that in
our cohort, almost 10 % of the patients died within 3–4
years after diagnosis although they were diagnosed in
mild-moderate functional stage and had most probably
not received pirfenidone during their lifetime. Cigarette
smoking is identified as a risk factor for IPF [13]. A study
from Sweden showed that smoking has a dose-related as-
sociation with increased risk of severe pulmonary fibrosis
[24]. Table 5 shows some of the baseline data compared
with published Danish and German cohorts [4, 14]. All
studies show similar patient characteristics, but also differ
in terms of the number of smokers and lung function.
Results suggest that studies based on informed consent
(such as InsightsIPF and FinnishIPF) in comparison to ie.
The Danish study may yield slightly different patient
cohorts in terms of disease severity, but do not rule out
local differences in terms of diagnostics, risk factors or
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disease course. It would be interesting to compare these
cohorts in terms of disease progression and mortality.
Study limitations and strengths
There are several weaknesses in this study. In Finland, IPF
is diagnosed almost exclusively at hospitals by respiratory
physicians, which means that patients living in the univer-
sity cities will attend the university hospitals. This, from
our perspective, limits the disease identification-related
bias to a minimum but it is still possible that some ILD
cases have been misdiagnosed and, therefore, not codified
as J84.1 or J84.9. The second limitation is that patients
were included only by informed consent, ruling out pa-
tients that met the diagnostic criteria but were unable or
unwilling to give informed consent. This approach was
chosen partially because of the local legislation on patient
data collection, but also to allow further contacts with
patients if needed. This is a major limitation in our study,
as the most advanced cases and rapid progressors
are probably lost from the cohort. However, we have
previously shown [1], that the published data on IPF varies
according to the method used, so that any method used is
going to yield in mere estimations of true prevalence.
The strength of this study is that all patient data were
carefully re-evaluated according to the current guide-
lines. Only a small percentage of patients were excluded
after the reassessment of the diagnostic HRCTs and
surgical lung biopsies, which in part proves the high
quality of the radiological and histopathological diagnos-
tics of the public health care system. This study was,
however, limited to university hospitals where the quality
of diagnostics should be high and the results might not
reflect the situation in smaller Finnish hospitals.
Conclusions
Our results indicate that all patients coded with ICD-10
codes J84.1 or J84.9 should not be used in epidemiologic
studies as equivalent to IPF. Only 20–30 % of these cases
were IPF assessed on the basis of patient records.
Histological and radiological re-evaluation still dropped out
12 patients out of these 123 patients. The nationwide
prevalence of IPF can be estimated to be 8.6/100 000. In
Finland IPF is diagnosed in mild-moderate stage, which with
emerging drug treatments may lead to improved prognosis.
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